JGC
ACRS icon

J. Goldman & Co’s Aclaris Therapeutics ACRS Stock Holding History

J. Goldman & Co’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-66,000
Closed -$452K – 329
2023
Q3 		$452K Buy
+66,000
New +$564K 0.02% 283

Other funds holding ACRS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return

J. Goldman & Co's ACRS Position: Q4 2023 in Review

J. Goldman & Co sold out of Aclaris Therapeutics (ACRS) in Q4 2023, closing a stake of 11,456 shares — an estimated $78.5K sold.

J. Goldman & Co first reported a position in ACRS in Q4 2016 and held it in 10 quarters. The position peaked at $3.65M in Q1 2021. 107 funds tracked by Wall St. Rank hold ACRS as of Q4 2023.

  • J. Goldman & Co reported no remaining Aclaris Therapeutics position as of Q4 2023 after selling out during the quarter.
  • J. Goldman & Co sold 11,456 Aclaris Therapeutics shares in Q4 2023, an estimated $78.5K.
  • J. Goldman & Co first reported a position in Aclaris Therapeutics in Q4 2016 and held it in 10 quarters.
  • J. Goldman & Co's Aclaris Therapeutics position peaked at $3.65M in Q1 2021.
  • 107 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q4 2023.

Based on J. Goldman & Co's 13F filing for Q4 2023, filed 14 Feb 2024.